Institutional members access full text with Ovid®

Share this article on:

SATB2 is a Novel Marker of Osteoblastic Differentiation and Colorectal Adenocarcinoma

Ordóñez, Nelson G. MD

Advances in Anatomic Pathology: January 2014 - Volume 21 - Issue 1 - p 63–67
doi: 10.1097/PAP.0000000000000001
New Antibody/Techniques

SATB2 is a nuclear matrix-associated transcription factor and epigenetic regulator that is involved in osteoblastic differentiation and is also expressed in the glandular epithelial cells of the lower gastrointestinal tract. Recent studies have shown that, because of its relative specificity for osteoblastic differentiation, SATB2 immunostaining could potentially be a useful adjunct for assisting in the differential diagnosis of both benign and malignant osteogenic tumors. In addition, because SATB2 is also a highly sensitive and specific marker for colorectal adenocarcinomas, it could also serve as a complementary marker in the differential diagnosis of a carcinoma of unknown primary origin.

Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

The author has no funding or conflicts of interest to disclose.

Reprints: Nelson G. Ordóñez, MD, Department of Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (e-mail: nordonez@mdanderson.org).

© 2014 by Lippincott Williams & Wilkins.